Perspectives du marché et avis des analystes :
La maladie de Crohn est une maladie inflammatoire chronique qui affecte principalement le tractus gastro-intestinal. Elle affecte généralement la partie terminale de l’intestin grêle et le début du gros intestin. La maladie se caractérise par une inflammation de la muqueuse du tube digestif, entraînant des symptômes tels que des douleurs abdominales, de la diarrhée et une malnutrition. La taille croissante du marché thérapeutique de la maladie de Crohn est attribuée à la prévalence croissante des maladies dans les pays occidentaux, en particulier aux États-Unis. De plus, les initiatives stratégiques des entreprises visant à rester compétitives sur le marché alimentent la croissance du marché. Une augmentation significative de l'utilisation de dispositifs médicaux avancés est susceptible d'entraîner de nouvelles tendances du marché thérapeutique de la maladie de Crohn au cours de la période de prévision.
Moteurs de croissance et défis :
La maladie de Crohn est un syndrome du côlon irritable, un trouble inflammatoire chronique de l’intestin sans remède spécifique. L'étiologie exacte de cette maladie n'est pas connue, mais elle est principalement le résultat d'une réponse immunitaire inappropriée dans l'intestin aux médicaments, aux toxines, aux infections et aux microbes intestinaux, entre autres facteurs environnementaux, en particulier chez un hôte génétiquement sensible. Selon la National Library of Medicine, la maladie de Crohn (MC) est plus fréquente dans les pays développés occidentaux, en particulier dans les pays d'Amérique du Nord et d'Europe du Nord, ainsi qu'en Nouvelle-Zélande. La maladie apparaît plus fréquemment chez les individus âgés de 15 à 30 ans et de 40 à 60 ans, et elle est plus importante dans les zones urbaines. L'incidence de cette maladie est élevée chez les personnes originaires des pays d'Europe du Nord et d'origine juive, soit 3,2/1 000. Cependant, des études récentes ont montré une augmentation significative de l'incidence en Asie, en Afrique et en Australasie, en raison de l'industrialisation rapide de la région. Ainsi, la prévalence stupéfiante de la maladie de Crohn dans la région concernée stimule le marché thérapeutique de la maladie de Crohn.
Selon l'Institut national de la santé, la maladie de Crohn représente un fardeau économique important avec des coûts de santé directs d'environ 3 500 USD par patient. par an en Europe. La maladie touche environ 322 personnes pour 100 000. Cependant, les taux de prévalence peuvent varier selon les pays. Plus de 50 % des patients atteints de la maladie de Crohn peuvent ne pas être formellement diagnostiqués ou présenter des symptômes identiques à ceux d'autres maladies du tube digestif. La maladie de Crohn est plus fréquente chez les femmes que chez les hommes, c'est-à-dire qu'elle peut toucher trois fois plus de femmes que d'hommes.
Les entreprises impliquées dans le développement de médicaments contre le syndrome du côlon irritable prennent des mesures constructives pour mettre en œuvre des programmes de sensibilisation dans le but faire face efficacement à ce syndrome en faisant connaître les symptômes, les diagnostics et les traitements. En 2018, Allergan PLC et Ironwood, en collaboration, ont lancé une plateforme de destination numérique interactive pour encourager les patients à s'informer et à agir contre les troubles du tube digestif. Ainsi, la prévalence croissante du syndrome du côlon irritable stimule la croissance du marché thérapeutique de la maladie de Crohn.
Aperçus stratégiques
Segmentation et portée du rapport :
L'analyse du marché thérapeutique de la maladie de Crohn a été réalisée en considérant les segments suivants : type de médicament, canal de distribution et géographie. Par classe de médicaments, le marché est segmenté en médicaments anti-inflammatoires, suppresseurs du système immunitaire, antibiotiques, produits biologiques, antidiarrhéiques et analgésiques. Le segment des produits biologiques détenait la plus grande part de marché en 2023. Le segment des médicaments anti-inflammatoires devrait enregistrer le TCAC le plus élevé au cours de la période 2023-2031.
En fonction de l'utilisateur final, le marché est divisé en pharmacies hospitalières et pharmacies cliniques. , et d'autres en ligne. Le segment des pharmacies hospitalières représentait la plus grande part de marché des produits thérapeutiques contre la maladie de Crohn en 2023. En termes de géographie, la portée du rapport sur le marché des produits thérapeutiques contre la maladie de Crohn couvre l’Amérique du Nord (États-Unis, Canada et Mexique), l’Europe (Espagne, Royaume-Uni, Allemagne, France, Italie et reste de l'Europe), Asie-Pacifique (Corée du Sud, Chine, Japon, Inde, Australie et reste de l'Asie-Pacifique), Moyen-Orient et Afrique (Afrique du Sud, Arabie saoudite, Émirats arabes unis et reste du Moyen-Orient et Afrique) et Amérique du Sud et centrale (Brésil, Argentine et reste de l'Amérique du Sud et centrale).
Analyse régionale :
L'Amérique du Nord est le plus grand contributeur au marché mondial des produits thérapeutiques contre la maladie de Crohn. croissance. On estime que l’Asie-Pacifique enregistrera le TCAC le plus élevé du marché entre 2023 et 2031. Les progrès du marché en Amérique du Nord sont attribués à l’incidence croissante des maladies chroniques, aux progrès technologiques et à l’accès à des produits médicaux technologiquement avancés, à l’augmentation de la population gériatrique et à la présence d’acteurs clés du marché impliqués dans le développement de produits nouveaux et existants. Les États-Unis détenaient la plus grande part de marché des produits thérapeutiques contre la maladie de Crohn en Amérique du Nord en 2023.
Marché des produits thérapeutiques contre la maladie de Crohn, par canal de distribution – 2023 et 2031
Développements de l'industrie et opportunités futures :
< Les prévisions du marché thérapeutique de la maladie de Crohn sont estimées sur la base de divers résultats de recherche secondaires et primaires, tels que des publications clés de l'entreprise, des données d'association et des bases de données. Selon les communiqués de presse de la société, les principaux développements réalisés par les principaux acteurs opérant sur le marché thérapeutique de la maladie de Crohn sont répertoriés ci-dessous :
•En 2023, la Food and Drug Administration (FDA) des États-Unis a approuvé la première pilule orale : Rinvoq (upadacitinib) — pour traiter la maladie de Crohn modérée à sévère. Rinvoq est destiné à traiter les patients adultes qui n'ont pas pu être traités avec succès avec des candidats médicaments bloquant le facteur de nécrose tumorale (TNF). En 2022, la FDA a approuvé Skyrizi pour le traitement des adultes atteints de cas de maladie de Crohn active modérée à sévère. « En 2021, AbbVie Inc. a annoncé le lancement de l'essai de phase 3 sur le risankizumab pour le traitement de la maladie de Crohn. Le risankizumab est un anticorps monoclonal humanisé qui cible sélectivement la voie de l'interleukine-23 (IL-23). L'essai vise à évaluer l'efficacité et l'innocuité du risankizumab chez les patients atteints de la maladie de Crohn modérée à sévère. En 2021, Takeda Pharmaceutical Company Limited a annoncé le lancement de l'essai de phase 3 du composé oral TAK-721 pour le traitement de la maladie de Crohn. TAK-721 est un antagoniste sélectif du récepteur de chimiokine CXCR3. L'essai vise à évaluer l'efficacité et l'innocuité du TAK-721 chez les patients atteints de la maladie de Crohn modérée à sévère. Paysage concurrentiel et entreprises clés :
Abbvie, Inc. ; Johnson et Johnson Private Limited ; GlaxoSmithKline Plc ; Merck et Cie., Inc. ; Novartis Ag; Société Celgène ; Genentech ; Pfizer Inc. ; Sciences de la santé Nestlé ; et Boehringer Ingelheim GmbH font partie des principaux acteurs présentés dans le rapport sur le marché des produits thérapeutiques contre la maladie de Crohn. De plus, plusieurs autres acteurs ont été étudiés et analysés au cours de l’étude pour avoir une vision holistique du marché et de son écosystème. Ces sociétés se concentrent sur l'expansion géographique et le lancement de nouveaux produits pour répondre à la demande croissante des consommateurs du monde entier et élargissent leur gamme de produits avec des portefeuilles spécialisés. Leur présence mondiale leur permet de servir une large clientèle, facilitant ainsi l’expansion du marché.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Crohn’s disease therapeutics market, based on drug class, is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain reliever. In 2023, the biologics segment held the largest Crohn’s disease therapeutics market share. The Crohn’s disease therapeutics market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy, online pharmacy. In 2023, the hospital pharmacy segment held the largest Crohn’s disease therapeutics market share and is anticipated to record the highest CAGR during 2023–2031.
The Crohn’s Disease Therapeutics Market majorly consists of the players such Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim Gmbh
Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.
Based on geography, the Crohn’s Disease Therapeutics Market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global Crohn’s Disease Therapeutics Market. Asia Pacific is expected to register the highest CAGR in the Crohn’s Disease Therapeutics Market during 2023–2031.
The increasing burden of irritable bowel syndrome, and the increasing in number of FDA approval and drug development bolster the Crohn’s disease therapeutics market size. However, the high cost of the treatment hinders the Crohn’s disease therapeutics market growth.
The List of Companies - Crohn's Disease Therapeutics Market
- ABBVIE, INC.
- JOHNSON AND JOHNSON PRIVATE LIMITED
- GLAXOSMITHKLINE PLC
- MERCK AND CO., INC.
- NOVARTIS AG
- CELGENE CORPORATION
- GENENTECH
- PFIZER INC.
- NESTLe HEALTH SCIENCE
- BOEHRINGER INGELHEIM GMBH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)